Join MySLAS Social

Editorial Archive

January 23, 2012
The Intricacies of Technology Transfer: Shaping Future Laboratory Work and a New SLAS Special Interest Group

If the pharmaceutical workplace model were a shapely wedge of clay ready to be retooled, contract organizations might be the hands that create its next form. How will science professionals cope with the transition of their roles and the transfer of technology to these core components of a decentralized model?

January 16, 2012
Navigating the Oceans and Prepping Young Explorers – A Good Day's Work for Bob Ballard

It's about the tools. Underwater discovery has been fascinating explorers for years but the risks to personal safety, costs to dive and time commitments so high it hindered progress. Enter SLAS2012 Keynote Speaker Bob Ballard and his amazing team of scientists, technologists and plain old big thinkers. Add a remotely operated vehicle or two and incredibly powerful Internet capabilities and the game is completely different. It is played on man's terms and much of it happens above water.

December 27, 2011
Epigenetics: Working Toward the Answers

Epigenetics. You can hardly glance at the scientific literature – and even mainstream media – without seeing something about epigenetics pop up. A simple Google search turns up more than 3 million entries. It has been heralded by most as "so much larger than the genome space." But, what does epigenetics mean to SLAS members involved in laboratory science and technology?

December 19, 2011
Chipping Away at the Future: Labs, Lungs, Livers and Perhaps Even Humans On-a-chip

"Drug toxicity is one of the most common reasons why promising compounds fail. We need to know which ones are safe and effective much earlier on in the process. This is an unprecedented opportunity to speed development of effective therapies, while saving time and money." – Francis S. Collins, M.D., Ph.D., director, National Institutes of Health (NIH News, September 16, 2011)

December 6, 2011
Bridging the Valley of Death: How Can Academia and Pharma Best Work Together?

The National Institutes of Health (NIH) calls the process of translating basic research into a viable product the "Valley of Death." They define it as the period of transition when a developing technology is seen as promising, but is too new to validate its commercial potential and unable to attract the necessary funding for its continued development.

November 22, 2011
Member Profile: Shalini Prasad

She compares her job to a stage performance: Capturing the audience, inspiring their imaginations, putting in a bit of sparkle so they will share her vision. Like a performer, she will travel thousands of miles and entertain many audiences before the year is over. Like a great actor, she will smile through life's challenges, including removing her shoes through one more airport security check.

November 10, 2011
Ready to Forge a Career Outside of Pharma?

It's fair to say that currently, the majority of SLAS's 15,000+ members are working in drug discovery and/or drug development in pharmaceutical companies, biotechs, academia and government. However, a growing percentage of the membership is made up of scientists and laboratory automation specialists who are forging careers in other industries—notably, clinical diagnostics, food and agricultural sciences, forensics and security sciences, petrochemical and energy and even consumer products.

October 27, 2011
Member Profile: Kamlesh Patel

Kamlesh Patel, Ph.D., is currently the department manager for the Advance Systems Engineering and Deployment group at Sandia National Laboratories in Livermore, CA. At LabAutomation2011, he won the SLAS Innovation Award for his outstanding podium presentation, "Preparation of Nucleic Acid Libraries for Ultra High-Throughput Sequencing with a Digital Microfluidic Hub." He serves SLAS2012 as both a session and track chair.

October 18, 2011
Innovation in Education: Bridging the Gap between the Lab and Careers in Life Science Companies

"Today the most exciting work in life sciences, engineering, and management is happening in the biosciences industry. To translate new discoveries into applications that improve the human condition, industry demands a new kind of professional - scientifically proficient and managerially savvy." – Keck Graduate Institute

October 7, 2011
Tackling Chemical Space: All Hands on Deck

Different angles. Varying approaches. Deep-thinking. Exploring any and all possibilities. The selection of valuable chemotypes from the expanse of known chemical space is a primary activity for all pharmaceutical institutions. Many strategies have been used to accomplish this task.

October 3, 2011
Remembering James N. Little, 1940-2011

Let's remember and celebrate a very special person – James N. Little.

September 27, 2011
Women in Chemistry: Progress Made, but Obstacles Remain

The world is in the midst of the International Year of Chemistry 2011 (IYC 2011), a global "celebration of the achievements of chemistry and its contributions to the well-being of humankind." An initiative of the International Union of Pure and Applied Chemistry (IUPAC) and of the United Nations Educational, Scientific, and Cultural Organization (UNESCO), the year-long celebration involves chemical societies, academies and institutions worldwide and is aimed at promoting international scientific collaboration. In support of IYC 2011, close to 100 countries registered more than 600 events and 1,200 activities.

September 14, 2011
Birds of a Feather: SLAS Special Interest Groups

SLAS is committed to being a member-driven scientific society. The strength of its active grassroots network is what gives SLAS such a meaningful grip on strategic direction and priorities. Everything from conference programs and events to journal content and newsletters uses the needs and wants of the SLAS scientific community as the compass that guides focus and development.

September 7, 2011
Next-Gen Sequencing: Lost in Translation?

"Genomics has certainly been overhyped – and so far failed to deliver on its promises. Many intelligent people have relegated the idea to the dusty corner shared by hopes for cold fusion, world peace and World Series rings for the Chicago Cubs," writes the author of a recent Forbes article, "Gene Machine." But while some people pooh-pooh the potential payoffs of genomic sequencing, others are working hard to help make them happen – but in so doing, have identified some formidable obstacles.

August 24, 2011
Ion Channel Biologists Making Great Strides

Drug discovery takes a long time. Most readers of the SLAS Electronic Laboratory Neighborhood would agree with the statement above. No surprises there. But, those working in the ion channel field might also add – we’re moving faster than we did just a few years back.

August 9, 2011
SLAS Member Profile: Robert M. Campbell – Drum Roll Please!

Robert M. Campbell, Ph.D., is senior research advisor at Eli Lilly and Company in Indianapolis, IN, where he heads the Cancer Cell Growth and Epigenetics Group. He recently spent two-and-a-half years in Singapore, directing an oncology research group for Lilly. Campbell serves SLAS as editor-in-chief of the Journal of Biomolecular Screening, a position he has enjoyed for three years.

August 1, 2011
Translational Medicine: Realities, Eventualities and Implications for the SLAS Community

Defining translational medicine isn't easy. According to some experts, the term has almost as many definitions as practitioners. "It reminds me of the story about the blind men and elephant; people tend to define translation as their part of drug development," Edward Spack of SRI International joked in the "Career Advice" section of Science magazine several years ago. "Speak to anybody from any company or academic institution and they'll have a new focus on it and a host of names," observed Trevor Mundel of Novartis in the same article. Indeed, the field is so huge, the American Association for the Advancement of Science (AAAS) now has an entire journal devoted to translational medicine.

July 6, 2011
SLAS Explores the Indian Landscape

In May 2011, SLAS sent a delegation of guest speakers to address laboratory science and technology issues as part of the Pharma+Bio educational program presented at the 2011 ChemTECH World Expo in Mumbai, India. This important annual event traditionally focuses on pharmaceutical manufacturing topics. SLAS was invited to participate in 2011 to assist the ChemTECH Foundation in expanding its scope to include pharmaceutical research and development.

July 6, 2011
Andy Zaayenga: Nature is a wonderful thing…

Andy Zaayenga is vice president of business development at HighRes Biosolutions, a company focused on the design and construction of innovative robotic systems and laboratory devices used by pharmaceutical and biotech companies and academic research laboratories. Prior to joining HighRes Biosolutions in December 2009, Zaayenga held senior management positions at SmarterLab, Tecan REMP, TekCel (Hamilton Storage Technologies) and Zymark (Caliper Life Sciences). He has been involved in laboratory automation since 1989. Zaayenga currently serves SLAS as secretary and also is active in the Laboratory Robotics Interest Group (LRIG) and the International Society for Biological and Environmental Repositories (ISBER) among others.

July 6, 2011
Stem Cells Moving into the Mainstream of Drug Discovery: Time to Get on Board

Much has happened in the field of stem cell research. In fact, we’ve recently moved past the honeymoon stage, during which, in our unbridled enthusiasm, we felt as though stem cells could solve everything from early stage drug-discovery mistakes to full-blown disease states. Now we’re in the stage where it’s obvious that stem cells have tremendous promise in a number of different areas, but we also recognize that it will take much more time and work before that promise can be fully realized.